These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7856232)

  • 1. Unsaturated fatty acids in the management of hyperlipidemias.
    Crepaldi G; Zambon S; Manzato E
    World Rev Nutr Diet; 1994; 76():38-40. PubMed ID: 7856232
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
    Carmena R
    Rev Esp Cardiol; 1995 Jan; 48(1):59-65. PubMed ID: 7878284
    [No Abstract]   [Full Text] [Related]  

  • 3. [Protective effect of monounsaturated and polyunsaturated fatty acids on the development of cardiovascular disease].
    Aguilera CM; Ramírez-Tortosa MC; Mesa MD; Gil A
    Nutr Hosp; 2001; 16(3):78-91. PubMed ID: 11475681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the effects of dietary n-3 fatty acids (Maxepa) on plasma lipids and lipoproteins in patients with hyperlipidaemia.
    Simons LA; Hickie JB; Balasubramaniam S
    Atherosclerosis; 1985 Jan; 54(1):75-88. PubMed ID: 3888229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of dyslipidemia].
    Cybulska B
    Pol Merkur Lekarski; 2002 Nov; 13 Suppl 1():11-2. PubMed ID: 12621774
    [No Abstract]   [Full Text] [Related]  

  • 6. Frequency of creatine kinase elevation during treatment with fluvastatin.
    Benghozi R; Bortolini M; Jia Y; Isaacsohn JL; Troendle AJ; Gonasun L
    Am J Cardiol; 2002 Jan; 89(2):231-3. PubMed ID: 11792351
    [No Abstract]   [Full Text] [Related]  

  • 7. Dietary monounsaturated versus polyunsaturated fatty acids: which is really better for protection from coronary heart disease?
    Lada AT; Rudel LL
    Curr Opin Lipidol; 2003 Feb; 14(1):41-6. PubMed ID: 12544660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed hyperlipemia, a sixth type of hyperlipoproteinemia.
    Brown HB; Lewis LA; Page IH
    Atherosclerosis; 1973; 17(2):181-96. PubMed ID: 4709119
    [No Abstract]   [Full Text] [Related]  

  • 9. Steatosis and collagen content in experimental liver cirrhosis are affected by dietary monounsaturated and polyunsaturated fatty acids.
    Fernández MI; Torres MI; Gil A; Ríos A
    Scand J Gastroenterol; 1997 Apr; 32(4):350-6. PubMed ID: 9140157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Eicosapentaenoic acid ethyl esters].
    Ohtsuka S
    Nihon Rinsho; 2007 Jul; 65 Suppl 7():489-93. PubMed ID: 17824076
    [No Abstract]   [Full Text] [Related]  

  • 11. Nutrition management of hyperlipidemias.
    Connor WE; Connor SL
    Curr Concepts Nutr; 1979; 8():179-216. PubMed ID: 393468
    [No Abstract]   [Full Text] [Related]  

  • 12. Maxepa--Eskimos, fish oils and ischaemic heart disease.
    Drug Ther Bull; 1988 Oct; 26(22):85-6. PubMed ID: 3053081
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of metabolic disorders with fluvastatin after renal transplantation.
    Podder H; Gerõ L; Földes K; Szabó J; Lazar N; Járay J
    Transplant Proc; 1997; 29(1-2):216-9. PubMed ID: 9122968
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of clofibrate on unsaturated fatty acids in lipid fractions of sera in patients with hyperlipemia].
    Felt V; Husek P
    Vnitr Lek; 1976 Mar; 22(3):256-61. PubMed ID: 1266086
    [No Abstract]   [Full Text] [Related]  

  • 15. The Hyperlipidemic Subject with Multiple Risk Factors: A Comprehensive Approach. Proceedings of a symposium. Jerusalem, Israel, September 5, 1993.
    Am J Med; 1994 Jun; 96(6A):1S-93S. PubMed ID: 7912474
    [No Abstract]   [Full Text] [Related]  

  • 16. Fluvastatin increases LDL particle size and reduces oxidative stress in patients with hyperlipidemia.
    Yoshino G; Hirano T; Kazumi T; Takemoto M; Ohashi N
    J Atheroscler Thromb; 2003; 10(6):343-7. PubMed ID: 15037823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fluvastatin in a comparative study. Are there substance-specific differences between various CSE-inhibitors?].
    Internist (Berl); 1999 Mar; 40(3 Suppl Gibt Es):1-4. PubMed ID: 10192028
    [No Abstract]   [Full Text] [Related]  

  • 18. What a dietitian should know about hyperlipidemia.
    Brown HB; Farrand M
    J Am Diet Assoc; 1973 Aug; 63(2):169-70. PubMed ID: 4352329
    [No Abstract]   [Full Text] [Related]  

  • 19. [Long-term administration of tyquanol in the treatment of patients with ischemic heart disease in combination with hyperlipidemia].
    Panchenko VM; Ershov AA; Isaev VA
    Klin Med (Mosk); 2003; 81(3):40-2. PubMed ID: 12698850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docosahexaenoic acid but not eicosapentaenoic acid increases LDL particle size in treated hypertensive type 2 diabetic patients.
    Woodman RJ; Mori TA; Burke V; Puddey IB; Watts GF; Best JD; Beilin LJ
    Diabetes Care; 2003 Jan; 26(1):253. PubMed ID: 12502701
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.